ADAMTS13 and thrombotic thrombocytopenic purpura: This raises the question of whether alemtuzumab may be associated with the development of TMA via multiple mechanisms, including through the induction of autoantibodies (which may target ADAMTS13, ie, TTP), as well as independent of ADAMTS13 autoantibody formation.